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Abstract 
 
The ability to preserve mammalian cells has long been a critical part of cell-based 
research for several reasons.  It allows for the transport of cells between laboratories 
or sites, ensures the availability of consistent starting material for the research 
through the establishment of cell banks and can uncouple cell-based assays from the 
culture process.  Although cryopreservation, whether conventional slow freezing or 
vitrification, is widely used as a method for preserving cells long-term, it can result in 
low cell recovery post-thaw and the cryoprotective agents used in the freezing 
medium can be cytotoxic.  With the emergence of a cell-based therapies industry, 
where clinical grade cells will need to be stored and transported, there is a growing 
need to develop scalable GMP-compatible preservation methods that retain not just 
high cell viability but also clinical efficacy.  With these issues in mind, this review will 
explore two alternatives to cryopreservation: cell desiccation for long-term storage of 
cells and the short-term storage of cells under hypothermic (>0°C) conditions. 
 
Introduction 
Cell-based therapies are part of a growing healthcare industry and are estimated to 
be worth $5 billion by 2014 (1).  Such treatments have typically involved harvesting 
material such as bone marrow or islet cells from donors and transplantation or 
transfusion of freshly isolated or expanded cells.  Cryopreservation, however, 
enables ‘off the shelf’ allogeneic therapies to be generated as the product, i.e. the 
cells, can be manufactured at a site physically separate from the clinic, stored and 
shipped as required.  It also allows the generation of master and working banks of 
cells for allogeneic therapies and time for extensive QC and safety testing to be done 
before a product lot is released.  Examples of cryopreserved cell therapies currently 
in clinical trials or use include CTX0E03 neural stem cells (ReNeuron Ltd, UK; (2)), 
Prochymal® (Osiris Therapeutics Inc, USA; (3)) and Dermagraft® (Advanced 
BioHealing, USA; (4)).   Cryopreservation also underpins the growing business of 
cord blood banking.  Despite its widespread use, there are several issues associated 
with the cryopreservation of cells and these will be briefly discussed before two 
alternatives to cryopreservation, namely cell desiccation and hypothermic storage, 
are explored. 
 
Issues associated with the cryopreservation of mammalian cells.  
Although cryopreservation, whether conventional slow freezing or vitrification, is 
widely used as a method for preserving cells long-term, it can result in low cell 
recovery post-thaw.  For instance, several studies reported poor survival and 
recovery rates of between 0 and 30% of human embryonic stem cell colonies or 
clumps when a slow freezing protocol was used (5-8).  Furthermore, although cell 
survival or viability is clearly an important measure of cryopreservation success, it is 
also important that cells retain their function long-term post-thaw, particularly when 
considering clinically relevant cells.  For example, protocols have now been 
developed that enable cryopreservation of human hepatocytes from donor livers for 
cell transplantation.  Although high numbers of viable cells can be recovered post-
thaw, large proportions of cells loose their ability to attach to surfaces which is key 
during engraftment, and their metabolic functions are altered (9), indicating further 
improvements still need to be made. 
 
Key to the success of any cryopreservation protocol is the use of cryoprotective 
agents (CPAs).  One of the most commonly used CPAs is DMSO, despite the fact 
that it is reported to be toxic to cells (10) and has been linked to cell differentiation 
(11).  Cells therefore need to be processed rapidly and ideally at low temperatures.  
Although this may be practical on a small scale, this becomes more difficult when 
processing cells at an industrial scale, which could take upwards of an hour (12).  
Furthermore, DMSO has also been reported to cause adverse reactions in patients 
(13) and so cells may need to be washed extensively prior to infusion or 
transplantation into patients.  This extra processing step can results in significant cell 
loses (14), thus it is clear that protocols that avoid or minimise the use of DMSO 
must be considered, especially for preservation of cell-based therapies.  
 
Given the large numbers of cells that may be required for allogeneic cell-based 
therapies (15) it is also important that cryopreservation protocols are developed that 
are scalable and GMP compliant.  Although conventional slow freezing protocols are 
adaptable, vitrification is not a truly scalable process (10, 15, 16).  Vitrification also 
poses extra risks as cells in open cryocontainers are exposed directly to liquid 
nitrogen which can contain contaminants such as microorganisms (17).  With all 
frozen cells, whether conventionally frozen or vitrified, it is also important that they 
are stored appropriately, with no fluctuations in temperature (10, 18).  This means 
careful environmental control is required, especially during transport. Transport of 
vitrified cells can, for instance, be very expensive as dry shippers, which hold 
samples at -150°C without the risks associated with transporting liquid nitrogen, are 
required to prevent any partial thawing of the cells (10, 18). 
 
Notably, a great deal of research is on-going to improve current cryopreservation 
protocols and overcome these issues.  Some of these innovations have recently 
been reviewed elsewhere (10, 15, 19) but, for example, using BHK cells, the impact 
of prolonged exposure (up to 5 hours) to DMSO on cell recovery and therefore what 
the true processing window for banking large numbers of cells is, was determined 
(12).  The authors found that if using cryobags the banking should be done within 
1.5-2 hours at room temperature.  Furthermore, Hunt and colleagues found that 
CD34+ cells could be exposed to 25% (w/w) DMSO for up to 1 hour at 2°C with no 
significant loss in the cells ability to generate colony forming units (20).  Although the 
authors only looked at exposure of freshly isolated cells to DMSO and not the impact 
that long-term exposure followed by freezing has on cell recovery, it is nonetheless 
encouraging to see that process conditions are starting to be defined beyond simply 
‘work quickly’.  The use of closed cryocontainers for vitrification to avoid direct 
exposure to liquid nitrogen is also being investigated (7, 21), as are ‘bulk’ vitrification 
methods (22), although even these are still relatively small scale (15).  Thus, 
although improvements are being made to the cryopreservation methods, it is worth 
exploring whether a preservation method, such as desiccation or hypothermic 
storage, which results in products that can be maintained at room temperature or in a 
refrigerated unit and could avoid the use of DMSO altogether, are viable alternatives.  
 
Alternatives to Cryopreservation: 
 
Dry preservation 
 
One alternative to cryopreservation is to avoid low temperature storage and transport 
altogether by desiccating cells as dried formulations could be kept at room 
temperature.  If feasible this would be both economically and practically 
advantageous, especially for long-term storage of cells. Although drying cells 
generally leads to membrane damage, protein denaturation and subsequent cell 
death, the inherent capacity of some organisms such as yeast cells and fungal 
spores to survive almost complete dehydration (23) suggests ‘safe’ dehydration and 
rehydration of mammalian cells should be possible.  Here efforts to both freeze dry 
(lyophilise) and simply desiccate cells by, for instance, vacuum desiccation, will be 
reviewed. 
 
Freeze drying, or lyophilisation, is typically used to preserve bacterial cells and fungi.  
Briefly, the process comprises three stages:  freezing in order to partly crystallise the 
solvent so that it can be separated from the solutes, sublimation of the resultant ice 
(primary drying phase) and finally, a secondary drying phase where the majority of 
the remaining moisture is removed by desorption (23, 24).  Just as cryoprotectants 
are used in cryopreservation, cells can be pre-treated and indeed lyophilised in the 
presence of lyoprotectants, to minimise cell damage during the process. One 
compound that has been particularly researched is trehalose, a hydrophilic 
disaccharide which is known to accumulate in desiccation tolerant organisms (25).   
 The key challenge in using trehalose as a lyo- or indeed cryo-protectant is that it is 
membrane impermeable and thus achieving the intracellular concentrations of at 
least 100-200mM required for protection (26, 27) is non-trivial.  Several different 
approaches have been reported including using fluid phase endocytosis (28), 
microinjection (29), mutant bacterial toxins as pore forming proteins (26, 27), 
genetically modifying cells to synthesise trehalose themselves (30) or express a 
trehalose transporter on their plasma membranes (31), osmotic shock (32, 33), 
electroporation (34) and a biopolymer (PP-50; (35)).  How trehalose is currently 
understood to exhert its protective effects has been thoroughly reviewed in Crowe et 
al (25) and Ohtake and Wang (36) but includes its role as a water replacement inside 
cells and its effectiveness as a stable vitrification agent.  
 
Efforts to lyophilise mammalian cells have largely focused on trying to generate 
freeze-dried blood, with some studies showing that erythrocytes and platelets can be 
successfully lyophilised, stored and rehydrated, although the processes are not yet 
optimal (28, 37-40).  For instance, Goodrich et al (37) reported that based on their 
patented method of erythrocyte lyophilisation, which involves lyophilising cells in the 
presence of monosaccharides such as glucose, cells maintained their metabolic 
function following rehydration although they note that it takes several days to reach 
the 1-2% residual moisture content in the samples that allows for storage at ambient 
temperatures.  By chemically cross-linking cells in a reversible manner, Bakaltcheva 
and colleagues (39) were also able to successfully lyophilise erythrocytes, with less 
than 10% haemolysis reported in their optimal conditions.  However, a final moisture 
content of 10-15% meant that cells had to be stored at 4°C, not ambient 
temperatures.  At moisture contents of less than 10%, heamolysis upon rehydration 
increased significantly and the authors themselves raised concerns over the safety of 
transplanting these chemically treated cells into patients (39).  Platelets have also 
been successfully lyophilised using trehalose as a lyoprotectant though it has been 
noted that the density at which cells are lyophilised and the method of how cells are 
rehydrated have a significant impact on the success rate (28).  Nonetheless, results 
are promising as a recent study using a model of deep arterial injury has even shown 
that lyophilised human platelets, when reconstituted into platelet free plasma, 
retained their haemostatic properties (40).    
 
Although the genetic material of mouse embryonic stem cells, spermatozoa and 
sheep granulose cells has been preserved following freeze-drying (41-43), it was not 
until relatively recently that successful lyophilisation, storage for one week, and 
rehydration of nucleated cells was reported (44).  The authors demonstrated viability 
of mononuclear cells isolated from human umbilical cord blood following rehydration, 
with similar levels of CD34+ haematopoietic stem cells present in the population 
before and after preservation, which were capable of differentiating into a number of 
cell types.  In another study also focusing on haematopoietic progenitors, cells 
rehydrated after 4 week of storage at 25°C also retained their ability to generate 
colony forming units of different lineages.  Rehydrated cells produced between 35-80% 
colony forming units relative to unprocessed controls, depending on the lineage 
studied (45).   
 
For a number of therapies to be effective, cells may need to be encapsulated in order 
to, for instance, protect them from the patients’ immune system (46).  Therefore, the 
ability to freeze dry microencapsulated cells has also been investigated (47).  The 
viability of human retinal pigment epithelial cells, either dispersed or 
microencapsulated, was determined before and after the drying step and, although it 
was clear that drying drastically reduced viability of cells compared to freezing alone, 
this proof of principal study indicates that encapsulated cells could be freeze-dried.  
 
It is also possible to simply dry cells, under vacuum for instance, without the need for 
freezing.  As with lyophilisation, the use of a protective agent such as trehalose 
appears to offer protection (32), although cell injury/death can still occur if the drying 
process is too slow or not uniform enough, thereby exposing cells to severe osmotic 
imbalances (48, 49).  It has been shown that human mesenchymal stem cells (MSCs) 
exposed to trehalose and glycerol can be successfully dehydrated under vacuum 
and stored for 1 day (50).  Upon rehydration they regained their normal morphology 
and adhesive capability, were >90% viable, proliferated and maintained expression 
of key surface markers.  However, the authors did admit that there was a large 
amount of inconsistency from trial to trial and that longer storage times would need to 
be achieved.  As they did not measure the levels of intracellular trehalose achieved it 
is possible that variation in this between runs or simply insufficient trehalose loading 
overall affected the success rate of desiccation.   After expressing a trehalose 
transporter in CHO-cells, one group also reported that they could be successfully 
desiccated after loading with trehalose (31).  Membrane integrity was retained in 
approximately 80% of cells when moisture content was reduced to as little as 2.6 g 
water/g dry weight.  However, upon rehydration these cells exhibited a vastly 
reduced proliferative capacity compared to control cells.  Given that only ~23.5 mM 
intracellular trehalose concentrations were achieved, well below the 100 mM 
minimum mentioned earlier, it may be that with enhanced trehalose uptake the 
desiccation tolerance of CHO cells could also be improved.   
Although these reports are promising, indicating that desiccation of cells for long-
term storage may be possible in the future, there are several caveats.  Clearly, as 
already mentioned, storage times must be increased. Secondly, if cells are to be 
used in cell therapy, it is important that cells are not simply viable immediate post-
rehydration but retain normal function and clinical efficacy.  For example, one study 
reported that human bone marrow-derived MSCs could be freeze-dried (51) but, 
whilst initial recovery following rehydration was high (~70%), cells were unable to 
adhere to tissue culture plastic as normal and died within 1 week.  Similarly, Li and 
colleagues (52) successfully lyophilised Hep2G cells loaded with trehalose and 
modified to express two late embryogenesis abundant proteins which are associated 
with desiccation tolerance in anhydrobiotic animals and bacteria.  A very high level of 
membrane integrity was retained up on rehydration (98%), but cell growth was 
decreased compared to non-dried controls.  These studies highlight the need to look 
at the longer-term effects of these processes, not just immediate post-rehydration 
viability as the longer-term health of the cells may be compromised. 
 
Based on their findings in human foreskin fibroblasts, Puhlev et al (32) suggested 
that free-radical mediated damage may occur within desiccated cells. In order to 
achieve successful desiccation of nucleated cells we may therefore need to develop 
more complex protocols in order to overcome or prevent some of the stress that cells 
undergo during freezing and/or desiccation. For example, Chakraborty and 
colleagues have looked at ways to improve the drying process in order to reduce the 
osmotic stress that cells undergo.  They developed a spin-drying technique (49) 
which enabled a much lower water content to be achieved (0.16 g water/g dry weight) 
than in other studies, whilst retaining more than 95% membrane integrity of CHO 
cells.  However, the authors do admit that this is preliminary data and the longer-term 
impact of such extreme desiccation on the CHO cells was not investigated.  The 
impact of including additional lyoprotectants has also been explored.  For instance, 
one study transfected HEK293 cells with a stress protein, p26 from Artemia, and 
found that it has a synergistic effect with trehalose in improving cell viability following 
air-drying and rehydration.  An approximately 15% increase in membrane integrity 
was seen by the addition of the p26 as well as an increase in cell growth when cells 
had been dehydrated to 0.2 g water/g dry weight (53). 
 
Although these studies are interesting and show that improvements to protocols can 
be made, when working with clinically relevant cell types it is critical to remember that 
the cell is the product and will end up in a patient.  It will therefore be important to 
ensure that any additives used, or even the processes by which trehalose is loaded 
into cells, are accepted by the regulator.  It is important to note that lyophilisation has 
been used to preserve bacterial cells (54) and its use in the pharmaceutical industry 
means that there is a precedent for lyophilisation at a large scale, making it an 
attractive option which should continue to be investigated. 
   
Hypothermic Preservation 
Another potential alternative to cryopreservation for mammalian cells is hypothermic 
preservation where cells are stored at low but not freezing temperatures, effectively 
pausing the cells by slowing down metabolism, but without the dangers of ice 
formation.  At mild hypothermia (25-35°C) cells can still proliferate and grow and in 
fact, recombinant protein expression may be improved by culturing cells at reduced 
temperatures (55).  More severe hypothermia and refrigerated storage (0-10°C) is 
needed to arrest growth and pause the cells but this would nonetheless be preferable 
to storing cells in liquid nitrogen and the use of dry shippers.   This would be a short-
term preservation method and indeed, it is already used in the pharmaceutical 
industry as it can uncouple cell culture from cell-based assays (56).  It allows 
researchers to store cells for several days if a piece of equipment is double-booked 
or breaks down, rather having to dispose of plates of cells, saving time and money.  
Just like cryopreservation, hypothermic preservation also uncouples production or 
harvest of cells for cell-based therapies from their clinical use.  Although shelf life is 
more limited than with frozen products, this allows for an ‘off the shelf’ business 
model to exist, QC testing to be completed before cells are released and avoids the 
need for continuous culture.   
 Organs and blood fractions have long been stored at hypothermic temperatures prior 
to transplantation or transfusion (57, 58), however, cold injury can occur which can 
be amplified when cells are rewarmed.  The changes that cells undergo during cold 
exposure include: decreased membrane fluidity, changes in pH, osmotic imbalances, 
activation of the unfolded protein response, oxidative stress (59, 59, 60) and often 
lead to the initiation of apoptosis.  Therefore, several cold storage media have been 
designed to improve organ, tissue and cell preservation at temperatures in the range 
of 2-10°C.  These include University of Wisconsin Solution (UWS, also known as 
Viaspan), EuroCollins, Celsior, Custodiol (also known as Bretschneider’s HTK 
solution) and the HypoThermosol range (60-62). Importantly, HypoThermosol-FRS 
(BioLife Solutions, USA) is a protein and serum free solution which is manufactured 
to cGMP standards so that it is suitable for use in cell therapy products.  As the 
formation of reactive oxygen species is often implicated in cell injury, these solutions 
typically contain antioxidants such as glutathione (60, 63) as well as mimicking the 
ionic composition of the cells under cold temperatures, providing a pH buffering 
system and some nutrients. As an example the base formulation of HypoThermosol 
is given in Table 1 but it is notable that solutions containing iron chelators (60), 
apoptosis inhibitors (64) and even antifreeze proteins (65) have been tested.     
 
Hypothermic preservation of a range of cell types has been investigated, including 
hepatocytes (60, 66), MSCs (67), red blood cells (58), neurons (68), renal cells (69) 
and endothelial cells (59, 62). Despite the use of specially formulated preservation 
media, cell recovery from hypothermic storage can still be variable and is very 
dependent on the medium composition.  For example, survival of human hepatocytes 
seeded in monolayer culture and stored at 4°C for up to 1 week in UWS was less 
than 20% (60).  An optimised solution based on Custodiol and containing iron 
chelators, however, improved cell survival drastically such that cell death was less 
than 20% (60).  Similarly, in a study using several cells types, Mathew and 
colleagues found that each was best preserved in a slightly different HypoThermosol 
variant (62).  For instance, HypoThermosol supplemented with Trolox and RGD 
peptide best supported the survival of skeletal muscle cells stored in suspension at 
4°C for 7 days whereas hepatocytes were best preserved in a formulation 
supplemented with a caspase inhibitor, FK041.  
 
Hunt and colleagues (70) also demonstrated that it is possible to store cells in their 
normal culture medium.  They reported that recombinant CHO and HEK293 cells 
(both adherent and suspension) could be paused for up to 3 weeks over a wide 
range of temperatures, from 4 to 24°C.  Cells retained their capacity for growth and 
protein production once rewarmed to 37°C.  Another study has shown that human 
embryonic stem cells in culture medium can also tolerate temperatures of 4 or 25°C 
for up to 48 hours with approximately 70% survival and retention of a normal 
karyotype and expression of pluripotency markers (71). This does not seem to be 
universally applicable though as, in contrast, when human bone marrow derived 
MSCs were stored at 4°C in their growth medium they failed to survive, although they 
could be successfully stored for up to 4 days in HypoThermosol-FRS (67).  Similar 
results were also obtained by Mathew et al when they investigated the preservation 
of several different cell types (62).  
 
It is important to note that, just as in the desiccation work, some studies have 
reported that although cell viability following hypothermic storage can be high, cell 
function can be negatively affected.  For instance, storing isolated human 
hepatocytes in HypoThermosol-FRS at 4°C for up to 72 hours resulted in a cell 
viability of approximately 70% which was a drastic improvement over cells stored in 
UWS or the base HypoThermosol medium.  However, despite cell viability being high, 
cell metabolic function, was typically half that of freshly isolated cells (63).  Another 
study which investigated whether bovine limbal epithelial cells could be stored at 4°C 
in calcium alginate hydrogels found that despite about 50% of cells extracted from 
the gels post-storage being viable, the colonies formed from these cells were 
noticeably smaller than those formed from cells that had not been stored (72). These 
studies highlight that just as with other methods of preservation, it is important to not 
just focus on cell viability upon rewarming but also cell function and growth. 
   
It is notable that many studies, including some of those referred to here, utilise 
adherent cells which have been seeded in plates, allowed to reach a certain degree 
of confluency and the growth medium is then replaced with hypothermic preservation 
solution before the plate is moved into cold storage.  Although this is suitable for cells 
that will be used in plate-based cell assays such as those commonly used in 
pharmaceutical research, it is not suitable for storage of cell-based therapies.  For 
example, a clinical dose of MSCs could exceed 2x108 cells (73) and in our hands a 
confluent T75 contains approximately 3 x106 MSCs [74] so a minimum of around 29 
T175 flasks would be required for a single dose. Aside from the logistics of storing or 
transporting such large numbers of tissue culture flasks containing the liquid 
hypothermic preservation medium, it is also easier for the clinicians to receive vials 
or bags of cells that are ready for transplantation or transfusion, without needing to 
harvest cells from flasks.  It is therefore important that anyone investigating the 
potential to store cells for cell-based therapies at 4°C does so under appropriate 
conditions.   
 
Overall, hypothermic preservation does overcome some of the issues with 
cryopreservation.  It avoids the use of DMSO, is amenable to scale up in that cells 
could be stored in vials or cryobags and GMP compliant preservation media is 
already available (Table 2).  However, results so far have indicated that with some 
tweaking of the preservation solution, most cells are amenable to hypothermic 
storage.  It will clearly always be a short-term solution compared to cryopreservation 
or indeed desiccation but, as is already apparent in organ transplantation and the 
blood banking industry, it has a role in getting cells from the site of harvest or 
production to the clinic.  It remains to be seen how widely applicable hypothermic 
storage of cells is when the long-term effects on cell function and the impact of 
preservation in suspension are explored in more detail.   
 
Conclusions and future perspectives 
Although cryopreservation is by far the most common method of preserving 
mammalian cells it is not without its disadvantages.  Here, two alternatives, 
summarised in Table 2, have been presented which could be used for either short or 
long-term preservation of cells.  As hypothermic storage has been used in organ 
transplantation for so long, this route may be more acceptable to the cell biology 
community and regulators but desiccation should continue to be explored as an 
alternative to cryopreservation.  As these methods evolve it will also be interesting to 
see whether, in order to extend the shelf life of products, these preservation methods 
are combined in the future.  For instance, one can envisage a scenario where cells 
are frozen in the first instance for long-term storage, then thawed, washed and 
resuspended in hypothermic storage medium for transport to the clinic as and when 
needed.  How cells will respond to these multiple stresses remains to be seen.   
   
Table 1: Formulation of the base HypoThermosol medium.  It has an osmolality of 
360 mOsm/kg. A vitamin E analogue, Trolox, is added to the base to generate 
HypoThermosol-FRS (Mathew 2004).  
Component  Concentration 
Sodium 100 mM 
Potassium 42.5 mM 
Magnesium 5 mM 
Calcium 0.05 mM 
Chlorine 17.1 mM 
H2PO4- 10 mM 
HCO3- 5 mM 
HEPES 25 mM 
Lactobionate 100 mM 
Glucose 5 mM 
Mannitol 20 mM 
Sucrose 20 mM 
Dextran-40 6% 
Adenosine 2 mM 
Glutathione 3 mM 
 
 
Table 2: Summary of whether desiccation or hypothermic storage overcome any of 
the issues surrounding cryopreservation of mammalian cells.  TBC; to be confirmed 
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